Oncology – Page 32

First-in-Human Results of Terbium-161 PSMA Radioligand Therapy in mCRPC: Insights from the VIOLET Study

By MedXY 08/02/2025

A phase 1/2 trial demonstrates the safety of [161Tb]Tb-PSMA-I&T, a novel dual beta-Auger radioligand, in heavily pretreated metastatic castration-resistant prostate cancer patients, supporting further clinical investigation.

Clinical Updates news Oncology Specialties

Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial

By MedXY 08/02/2025

Limertinib demonstrates superior progression-free survival and a comparable safety profile to gefitinib, supporting its use as a first-line therapy in EGFR-mutated locally advanced or metastatic NSCLC.

Clinical Updates news Oncology Specialties

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

By MedXY 08/01/2025

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Clinical Updates Gastroenterology Medical News Oncology Specialties

Interval Colorectal Cancer Risk and Outcomes after Positive FIT with Follow-Up Colonoscopy in Taiwan Screening Program

By MedXY 08/01/2025

A Taiwanese cohort study reveals higher interval colorectal cancer incidence and mortality after follow-up colonoscopy for positive FIT compared to negative FIT, highlighting risk stratification and adenoma detection rate impact on outcomes.

Clinical Updates Oncology Specialties

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer: New Therapeutic Prospects

By MedXY 08/01/2025

A phase 2 study shows that bevacizumab and erlotinib combination therapy offers notable tumor responses and survival benefits in both hereditary and sporadic papillary renal-cell carcinoma, with manageable toxicity.

news Oncology Specialties

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

By MedXY 08/01/2025

Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.

Clinical Updates news Oncology Specialties

Expanding Nonoperative Management in Mismatch Repair–Deficient Early-Stage Solid Tumors: Phase 2 Evidence for Neoadjuvant PD-1 Blockade

By MedXY 08/01/2025

Neoadjuvant PD-1 blockade with dostarlimab enabled organ preservation and high recurrence-free survival in early-stage mismatch repair–deficient (dMMR) solid tumors, extending nonoperative management beyond rectal cancer.

Clinical Updates news Oncology Specialties

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

By MedXY 08/01/2025

A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.

Clinical Updates news Oncology Specialties

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

By MedXY 08/01/2025

Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.

Clinical Updates news Oncology Specialties

Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study

By MedXY 08/01/2025

Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.

news Oncology Respiratory Specialties

Comparative Efficacy and Safety of Prednisone and Methotrexate as First-Line Treatments for Pulmonary Sarcoidosis

By MedXY 08/01/2025

A recent multicenter trial demonstrates methotrexate's noninferiority to prednisone in improving lung function at 24 weeks in pulmonary sarcoidosis, with distinct side-effect profiles informing treatment choices.

Clinical Updates news Oncology Specialties

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.

news Oncology Specialties

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

By MedXY 07/31/2025

Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.

Clinical Updates news Oncology Specialties

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY 07/31/2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.

Clinical Updates news Oncology Specialties

Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity

By MedXY 07/31/2025

Dupilumab controls ADC-related skin toxicities more effectively than systemic steroids, reducing cancer treatment discontinuation and improving response rates.

news Oncology Specialties

Limited Direct Comparison of Me-Too Oncology Drugs with First-in-Class Agents: Clinical Implications and Regulatory Considerations

By MedXY 07/31/2025

Analysis of FDA approvals from 2009–2020 reveals only 29% of next-in-class oncology drugs underwent head-to-head RCTs against originals, with just 22% showing survival benefits, highlighting a need for incentivized comparative trials.

Clinical Updates news Oncology Orthopedics Specialties

Inconsistent Bone Health Management in Older Women With Breast Cancer: Insights From the Age Gap Study

By MedXY 07/31/2025

Significant variation exists in bone health management for older women receiving endocrine therapy for breast cancer, highlighting the need for standardized care.

Clinical Updates news Oncology Specialties

ED Intubation in Active Hemorrhage Linked to Increased Mortality: Insights from a Nationwide Cohort Study

By MedXY 07/31/2025

Intubation in the emergency department for trauma patients with active hemorrhage is associated with higher mortality, more ICU admissions, and greater transfusion needs compared to intubation in the operating room.

Clinical Updates news Oncology Specialties

Ovarian Cancer Risk Peaks Shortly After New IBS Diagnosis: Clinical Implications and Evidence Review

By MedXY 07/31/2025

A new IBS diagnosis is associated with a transiently increased risk of ovarian cancer, especially within the first 6 months, emphasizing the need for heightened clinical vigilance.

Medical News news Oncology Specialties

Obesity-Linked Liver Cancer: A Preventable Crisis on the Rise

By MedXY 07/31/2025

Over 60% of liver cancer cases are preventable, yet rising obesity and metabolic dysfunction threaten progress. The Lancet Commission outlines urgent strategies to curb a projected doubling of global liver cancer burden by 2050.